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Molecular alterations associated with liver metastases
development in colorectal cancer patients
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The Netherlands; 4Department of Molecular Biology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX
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BACKGROUND: Understanding the molecular biology of colorectal cancer (CRC) provides opportunities for effective personalised
patient management. We evaluated whether chromosomal aberrations, mutations in the PI(3)K signalling pathway and the CpG-
island methylator phenotype (CIMP) in primary colorectal tumours can predict liver metastases.
METHODS: Formalin-fixed paraffin-embedded material from primary colorectal tumours of three different groups were investigated:
patients with CRC without metastases (M0, n¼ 39), patients who were treated with hyperthermal intraperitoneal chemotherapy for
CRC metastases confined to the peritoneum (PM, n¼ 46) and those who had isolated hepatic perfusion for CRC metastases
confined to the liver (LM, n¼ 48).
RESULTS: All samples were analysed for DNA copy number changes, PIK3CA, KRAS, BRAF mutations, CIMP and microsatellite instability.
The primary CRCs of the LM group had significantly higher frequency of amplified chromosome 20q (P¼ 0.003), significantly fewer
mutations in the PI(3)K signalling pathway (P¼ 0.003) and fewer CIMP high tumours (P¼ 0.05). There was a strong inverse
correlation between 20q and the PI(3)K pathway mutations.
CONCLUSION: The development of CRC liver metastases is associated with amplification of chromosome 20q and not driven by
mutations in the PI(3)K signalling pathway.
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Colorectal cancer (CRC) is the second leading cause of cancer
death in the Western world. The WHO estimates that 945 000 new
cases occur yearly, with 492 000 deaths (Weitz et al, 2005). The
overall 5-year survival is 57%, and up to 50% of patients will
develop metastases. Distant metastases are responsible for the
great majority of CRC deaths, mainly due to liver metastases
(Welch and Donaldson, 1979; Galandiuk et al, 1992; Sadahiro et al,
2003). Of all patients who die of advanced CRC, 60–70% have liver
metastases (Weiss et al, 1986). Even with the use of targeted drugs,
the overall survival in patients with non-resectable CRC liver
metastases is only 2 years, and late detection of liver metastases is
still fatal. Hepatic resection is the only potentially curative
treatment for a subset of patients with colorectal liver metastases.
In these patients with resectable liver metastases, a 5-year survival
of 30% can be achieved, and up to 20% of this population will still
be alive after 10 years. The eligibility for hepatic surgery depends
on whether all metastases are resectable and an adequate liver
function can be maintained. There should be no extrahepatic
disease, with the possible exception of few resectable lung
metastases (Rees et al, 2008). Fong et al (1999) created a clinical
risk score to identify patients who would most benefit from liver
resection and showed that two of the five factors were determined
by the number and size of the metastases in the liver. Therefore,
early detection of liver metastases is of utmost priority and can
result in more radical surgery and thus long-term survival
(Rodriguez-Moranta et al, 2006).
The current tumour node metastases staging system of CRC has
great clinical utility for prognosis and adjuvant treatment decision,
but provides no information about a site-specific risk for liver
metastases. A better understanding of the molecular biology of
CRC progression has the potential to provide this information.
Colorectal cancer arises and processes through an adenoma–
carcinoma sequence. This adenoma–carcinoma sequence follows
well-defined steps of histological stages, each characterised by
distinct mutations in oncogenes and tumour suppressor genes
(Fearon and Vogelstein, 1990; Lengauer et al, 1997). The majority
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(85%) of CRC are chromosomal instable, characterised by allelic
losses, chromosomal amplifications, translocations, as well as gene
mutations (Lengauer et al, 1997; Thiagalingam et al, 2001; Jass
et al, 2002; Jass, 2007).
One of the pathways often affected in CRC is the PI(3)K
signalling pathway. This pathway has a central role in tumorigen-
esis by regulating cell growth, differentiation and apoptosis
(Vivanco and Sawyers, 2002; Samuels et al, 2004; Shaw and
Cantley, 2006). In this pathway, PIK3CA, KRAS and BRAF genes
are frequently activated by mutations in various tumour types,
including CRC (Samuels et al, 2004; Oikonomou and Pintzas, 2006;
Cardoso et al, 2007; Kato et al, 2007) with frequencies of 10–30%
(Samuels et al, 2004; Velho et al, 2005; Kato et al, 2007; Barault
et al, 2008; Nosho et al, 2008; Ogino et al, 2009b), 30–40%
(Vogelstein et al, 1988; Andreyev et al, 1998; Cardoso et al, 2007)
and 5–22% (Yuen et al, 2002; Cardoso et al, 2007), respectively.
Mutations in any one of these three genes will activate the PI(3)K
signalling pathway and increases the transcription of different
oncogenes, such as C-MYC, CREB, NF-kB and others (Barault et al,
2008), resulting in unrestricted cell growth.
There is a potential role of this signalling pathway in predicting
survival (Kato et al, 2007; Barault et al, 2008); however, little is
known about the relation between mutations in primary colorectal
tumours and the risk of developing liver metastases. Furthermore,
in our recent work we showed that an amplification of
chromosome 20q is strongly related with the development of liver
metastases (Bruin et al, 2010).
Here, we evaluated whether chromosomal aberrations and/or
mutations in the PI(3)K signalling pathway and CpG-island
methylator phenotype (CIMP) in primary colorectal tumours can
predict liver metastases. Improved understanding of the biological
mechanisms underlying liver metastases may allow tailored follow-up
and potentially adapted management in patients with early-stage CRC.
MATERIALS AND METHODS
Patients and tumour samples
Formalin-fixed paraffin-embedded material (FFPE) from primary
colorectal tumours of three different groups were investigated:
patients with CRC who had not developed metastases, median
follow-up 8 years (M0, n¼ 39); patients who had been treated with
hyperthermal intraperitoneal chemotherapy for synchronous or
metachronous CRC metastases confined to the peritoneum (PM,
n¼ 46) (Verwaal et al, 2003, 2008); and patients who had been
treated with isolated hepatic perfusion for CRC synchronous or
metachronous metastases confined to the liver (LM, n¼ 48) (van
Iersel et al, 2008). These three specific groups were selected to
identify specific markers for LM, which are not particular for other
metastatic localisations such as PM, nor characteristic for CRC that
do not metastasise. The LM and PM groups were carefully screened
at the time of diagnosis to ensure they were free of other distant
metastases (Marinelli et al, 1998; Verwaal et al, 2003). Clinical and
pathological characteristics were retrieved from computerised
medical registries and existing study databases (Marinelli et al,
1998; Verwaal et al, 2003; van Iersel et al, 2008).
We used anonymised tissue material from patients with consent
following standard operational procedures in the respective
hospitals, approved by the Institutional Review Board. Tissue
handling was anonymised following the Declaration of Helsinki.
DNA extraction and mutation analysis
DNA isolation was performed as described earlier (Joosse et al,
2007). Briefly, genomic DNA was isolated by proteinase K
digestion after deparaffination from 10 10 mm2 FFPE tissue
sections containing at least 70% tumour cells from both the M0
and PM group. For the LM group, DNA was isolated from FFPE
tissue block punches. These punches were taken out of the tissue
blocks in the area with at least 60% tumour cells.
For the mutation analysis, exons 9 and 20 of PIK3CA, exon 1 of
KRAS and exon 15 of BRAF were amplified by PCR and the
presence of mutations was detected by direct sequencing using the
BigDye Terminator Cycle Sequencing Kit (Applied Biosystems,
Carlsbad, CA, USA). For all PCR products with sequence variants,
both forward and reverse sequence reactions were repeated for
confirmation. Primers used for the amplification and the PCR
conditions are available upon request.
Microsatellite instability
Analysis of microsatellite instability (MSI) was performed by using
PCR and subsequent fragment analysis on an automated capillary
sequence machine (ABI, 3730). The following eight markers were
evaluated, including two mononucleotide markers (BAT 25 and
BAT 40) and six dinucleotide markers (D1S158, D2S123, D5S346,
D9S63, D17S250, D18S58). A tumour was considered to be MSI-
high when three or more markers showed instability, MSI-low
when one or two markers showed instability and MSI-stable when
none of the eight markers showed instability (Kets et al, 2008).
CIMP status
CpG-island methylator phenotype status was analysed by using the
methylation-specific multiplex ligation-dependent probe amplifi-
cation (MS-MLPA) kit (MRC-Holland, Amsterdam, the Nether-
lands; see Nygren et al (2005)). This MS-MLPA kit can be used to
detect aberrant methylation of eight CIMP-specific promoters for
CRC (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEU-
ROG1, RUNX3 and SOCS1) (Weisenberger et al, 2006; Ogino et al,
2009a). CpG-island methylator phenotype analysis was performed
according to the manufacturer’s protocol (SALSA MLPA kit,
ME042-A1 CIMP; MRC-Holland). CpG-island methylator pheno-
type-high was defined as 6–8 methylated markers using the eight-
marker CIMP panel and CIMP-low as 0–5 methylated markers
(Ogino et al, 2007, 2009a).
Chromosomal aberrations
DNA copy number changes were investigated using the 3.5k
bacterial artificial chromosomes (BAC) array performing array
comparative genomic hybridisation as described previously
(Joosse et al, 2009; Bruin et al, 2010). The human 3600 BAC/
PAC genomic clone set, covering the full genome at 1Mb spacing
used for the production of our arrays, was obtained from the
Welcome Trust Sanger Institute (http://www.sanger.ac.uk/).
Information on this clone set can be obtained at the BAC/PAC
Resources Center Website (http://www.bacpac.chori.org/). The
whole library was spotted in triplicate on every slide. To prevent
slide batch spotting bias, samples were hybridised in random order
(http://www.microarrays.nki.nl/).
Statistical analysis
A propensity score using the baseline clinical data was calculated
to compare the three patient groups (M0, PM, LM). The propensity
score was taken as the probability of liver metastases given a
patients’ age, sex, T-stage, N-stage and primary location in a
multinomial logistic regression model (D’Agostino Jr, 1998;
Gleisner et al, 2008).
Patients missing baseline clinical data were imputed using
median values. The association between genetic data (BRAF,
KRAS, PIK3CA mutations, PI(3)K signalling pathway (mutation in
at least one of the three genes) and CIMP) and the occurrence of
liver metastases was determined and adjusted for quartiles of the
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propensity score using exact Cochran–Mantel–Haenszel tests.
Fisher’s exact and Kruskal–Wallis tests were used to determine the
strength of associations between baseline clinical and pathological
characteristics and the occurrence of liver metastases.
20q gain status
To determine whether a tumour had a gained 20q arm, we
calculated average total copy numbers (TC) for 20q in each tumour
using the average log 2 (AL2) of the BAC clones mapped to 20q
(equation (1)). We assumed 70% tumour tissue in each sample,
making this a conservative estimate of copy number.
ð2AL2Þ  1
0:7
2þ 2 ¼ TC ð1Þ
We labelled all tumours with a TC 20q of 42.5 as 20q amplified
(Bruin et al, 2010).
RESULTS
Patient characteristics
Table 1 presents the clinical and pathological characteristics
for each of the three patient groups. Some of the patient
characteristics are different among groups owing to the selection
criteria employed for each group. These differences, however, were
accounted for by using a propensity score for the evaluation of LM
predictive markers (see below). More right-sided tumours were
included in the M0 group, whereas the PM and LM group consisted
of more left-sided colon and rectum tumours and of younger
patients. There were more T4 tumours in the PM group compared
with the M0 and LM group. As expected, the M0 group showed less
Nþ tumours. All patients in the M0, LM group and the
metachrone patients in the PM group achieved an R0 resection
for their primary tumour. The range of follow-up in the M0 group
of patients still alive without recurrent disease was 4.6–16.7 years
(median 8 years). Five patients in the M0 group died before 5 years
follow-up without metastases. Range of time between primary
diagnosis and diagnosis metastasis for metachrone LM and PM
patients is 3.4–37.5 and 5.5–94.0 months, respectively.
Mutation analysis
KRAS, PIK3CA and BRAF and PI(3)K signalling pathway
mutations In the combined study population (n¼ 133), BRAF
mutations were identified in 11 cases (8%), KRAS in 42 cases (32%)
and PIK3CA in 21 cases (16%) (Table 2).
No significant differences were observed for the propensity
score adjusted differences of PIK3CA, KRAS and BRAF mutations
Table 1 Patient characteristics
M0 (n¼ 39) PM (n¼ 46) LM (n¼ 48) Total (n¼ 133) P-valuea
Gender 0.001
Male 17 (44%) 23 (50%) 38 (79%) 78 (59%)
Female 22 (56%) 23 (50%) 10 (21%) 55 (41%)
Age o0.0001
Median (range) 63 (37–86) 51 (30–72) 55 (36–69) 56 (30–86)
Location o0.0001
Right colon 19 (49%) 13 (28%) 3 (6%) 35 (26%)
Left colon 14 (36%) 29 (63%) 32 (67%) 75 (56%)
Rectum 6 (15%) 4 (9%) 13 (27%) 23 (17%)
T 0.03
T2 0 (0%) 1 (2%) 5 (10%) 6 (5%)
T3 33 (85%) 34 (74%) 38 (79%) 105 (79%)
T4 6 (15%) 11 (24%) 3 (6%) 20 (15%)
Missing 0 (0%) 0 (0%) 2 (4%) 2 (2%)
N 0.001
N0 30 (77%) 19 (41%) 18 (38%) 67 (50%)
N+ 9 (23%) 26 (57%) 27 (56%) 62 (47%)
Missing 0 (0%) 1 (2%) 3 (6%) 4 (3%)
Presentation 0.004
Synchrone 0 (0%) 17 (37%) 33 (69%) 50 (38%)
Metachrone 0 (0%) 29 (63%) 15 (31%) 48 (33%)
Missing 39 (100%) 0 (0%) 0 (0%) 39 (29%)
Adjuvant chemotherapy o0.0001b
No 33 (85%) 10 (22%) 10 (21%) 53 (40%)
Yes 4 (10%) 19 (41%) 5 (10%) 28 (21%)
Synchroneb 0 (0%) 17 (37%) 33 (69%) 50 (38%)
Missing 2 (5%) 0 (0%) 0 (0%) 2 (2%)
RT pretreatment 0.004
Yes 0 (0%) 3 (7%) 9 (19%) 12 (9%)
No 39 (100%) 43 (93%) 38 (79%) 120 (90%)
Missing 0 (0%) 0 (0%) 1 (2%) 1 (o1%)
Abbreviations: CRC¼ colorectal cancer; HIPEC¼ hyperthermal intraperitoneal chemotherapy; LM¼ liver metastasis; PM¼ peritoneal metastasis. aP-value: association of
clinicopathological characteristic with CRC subgroup. bPatients who presented with synchronous metastasis in the LM and PM group could have received adjuvant chemotherapy
as a part of their metastasis treatment (HIPEC or liver perfusion). Of note, this adjuvant treatment was given after metastasis treatment and therefore had no influence on the
metastasis development.
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among the three groups (Table 2). KRAS and BRAFmutations were
not observed in the same tumour, which is consistent with
previous observations (Figure 1) (He et al, 2009).
For further analyses, we combined the M0 with the PM group
because no statistical differences were found for mutations in the
PI(3)K signalling pathway or the 20q status between these groups
(P¼ 0.83 and 0.86, respectively). The LM group showed a trend of
fewer KRAS mutations compared with the M0–PM group
(P¼ 0.06) and no BRAF mutations (Table 2).
In total, 62 (47%) cases showed activation of the PI(3)K
signalling pathway by having mutation in at least one of the three
genes (Table 2), where 50 (38%) cases had mutations in a single
gene and 12 (9%) cases had mutations in two genes (PIK3CA and
BRAF or PIK3CA and KRAS). We note that two patients were
missing either KRAS or BRAF data; however, they were classified
as having a pathway mutation owing to harbouring a PIK3CA
mutation. For nine patients, none of the mutations could be
assessed (7%). Remarkably, mutation of the PI(3)K signalling
pathway was significantly less present in the LM group compared
with the combined M0–PM group (P¼ 0.003). The LM group
showed 27% (13 out of 48) PI(3)K signalling pathway mutations,
whereas this was 62% (24 out of 39) and 54% (25 out of 46) in the
M0 and PM group, respectively.
CpG-island methylator phenotype CpG-island methylator pheno-
type status was significantly different among the three groups
(P¼ 0.03) (Table 2). The LM group revealed the lowest CIMP-high
rate of 4% (2 out of 48), whereas the M0 and PM groups had 18 and
30% of CIMP-high, respectively. This remained significantly
different when the LM group was compared with the M0–PM
group (P¼ 0.05). The difference between M0 and PM was not
significant (P¼ 0.18). According to the literature (Samowitz et al,
2005; Ogino et al, 2006), CIMP-high is tightly associated with
Table 2 Molecular analysis of primary CRC of M0, PM and LM patients
M0 vs PM vs LM LM vs M0-PM
M0 (n¼ 39) PM (n¼ 46) LM (n¼ 48) Total (n¼ 133) CMH exact P-valuea CMH exact P-valuea
BRAF
Wild type 33 (85%) 38 (83%) 44 (92%) 115 (86%)
Mutated 5 (13%) 6 (13%) 0 (0%) 11 (8%) 0.23 0.18
Missing 1 (3%) 2 (4%) 4 (8%) 7 (5%)
KRAS
Wild type 23 (59%) 27 (59%) 33 (69%) 83 (62%)
Mutated 16 (41%) 16 (35%) 10 (21%) 42 (32%) 0.12 0.06
Missing 0 (0%) 3 (7%) 5 (10%) 8 (6%)
PIK3CA
Wild type 30 (77%) 39 (85%) 40 (83%) 109 (82%)
Mutated 9 (23%) 7 (15%) 5 (10%) 21 (16%) 0.2 0.25
Missing 0 (0%) 0 (0%) 3 (6%) 3 (2%)
PI(3)K signalling pathwayb
Wild type 14 (36%) 17 (37%) 31 (65%) 62 (47%)
Mutated 24 (62%) 25 (54%) 13 (27%) 62 (47%) 0.01 0.003
Missing 1 (3%) 4 (9%) 4 (8%) 9 (7%)
CIMP
Low 32 (82%) 32 (70%) 44 (92%) 108 (81%)
High 7 (18%) 14 (30%) 2 (4%) 23 (17%) 0.03 0.05
Missing 0 (0%) 0 (0%) 2 (4%) 2 (2%)
20q Amplificationc
Low 15 (38%) 23 (50%) 8 (17%) 46 (35%)
High 10 (26%) 12 (26%) 25 (52%) 47 (35%) 0.01 0.003
Missing 14 (36%) 11 (24%) 15 (31%) 40 (30%)
Abbreviations: BRAF¼ B-type Raf kinase; CIMP¼CpG-island methylator phenotype; CRC¼ colorectal cancer; LM¼ liver metastasis; PI(3)K¼ phosphoinositide 3-kinase;
PIK3CA¼ phosphoinositide-3-kinase, catalytic, alpha polypeptide; PM¼ peritoneal metastasis. aCMH¼Cochran–Mantel –Haenszel tests propensity score adjusted P-values. bA
patient with mutations in one or more of the three genes (BRAF, KRAS, PIK3CA) was counted as a mutated case in PI(3)K signalling pathway. c20q low amplifications are defined as
amplifications smaller than the median of the mean 20q (cut-off 0.224 log 2) and 20q high vice versa.
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Figure 1 This figure shows the relation between the 20q gain status,
liver metastasis (LM) and the mutation status of BRAF, PIK3CA and KRAS.
Black means the patient is positive for either 20q gain, LM or one of the
mutations, whereas gray means that the patient was negative for these
measurements. White values indicate that these patients were not tested
for the condition. Red boxes indicate two distinct patient population,
highlighting the relation between 20q gain, LM and the mutations.
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BRAF mutation, which was also seen in our series (P¼ 0.003)
(Table 3).
Chromosomal instability and PI(3)K signalling pathway
mutations Our recent study had shown that the three groups
had an overall similar pattern of chromosomal aberrations.
Furthermore, chromosome 20q was significantly more gained
(20q high; above median of the mean log 2 20q) in the LM group
compared with the M0–PM group (KSE, Po0.05, Bonferroni
multiple testing corrected) (Bruin et al, 2010).
Here we observed a strong inverse correlation between 20q
amplification and PI(3)K signalling pathway mutation (Po0.0001)
(Table 4a). Predominantly patients who were 20q low showed a
PI(3)K signalling pathway mutation and vice versa (Table 4a and
Figure 1). Table 4b shows that patients who developed LM were
characterised by primary CRC with a 20q high (amplified) (62.5%)
profile and a wild-type PI(3)K signalling pathway, whereas the
M0–PM patients by a 20q low (49.1%) and a mutated PI(3)K
signalling pathway (Table 4b). In the LM group, only 12.5% of the
patients were 20q high in combination with a mutation in the
PI(3)K signalling pathway; 9.4% showed 20q low with a mutation
in the PI(3)K signalling pathway and 15.6% was 20q low with a
wild-type PI(3)K signalling pathway. The overall comparison of the
distributions of 20q and PI(3)K between LM and M0–PM patients
was significant (P¼ 0.0002).
MSI status Four out of 133 patients were identified as MSI-high,
with three MSI-high patients in the M0 group and one in the PM
group. No association between MSI and CIMP-high was observed
(Table 3).
DISCUSSION
The current standard for early detection of CRC liver metastases is
the evaluation by imaging tools including ultrasound, MRI and
PET/CT (Mauchley et al, 2005; Ruers et al, 2009). Furthermore,
periodic clinical assessment and laboratory tests (e.g., carcino-
embryonic-antigen tests, liver-function tests and complete blood
counts) are performed to monitor signs of recurrence. However,
these surveillance strategies have limitations owing to the lack of
sufficient sensitivity and specificity (Pfister et al, 2004).
It is generally believed that circulating tumour cells, tumour-
specific DNA methylation markers, gene expression profiles and
MSI profiling may indicate which CRC patients are at higher risk
to develop a recurrence. In addition, chromosomal instability of
specific chromosomes, for example, 18q or 20q, have been
associated with poor prognosis and related to liver metastases,
respectively (Nanashima et al, 1997; Hidaka et al, 2000; Eschrich
et al, 2005; Popat et al, 2005; Barrier et al, 2006; Cardoso et al,
2007; Lin et al, 2007; Anjomshoaa et al, 2008; Bruin et al, 2010; Kim
et al, 2010; Salazar et al, 2011).
In this study of primary colorectal tumours, we aimed to
evaluate the combined value of mutations in the PI(3)K signalling
pathway, the CIMP, MSI and the aberration of chromosome 20q in
primary colorectal tumours to predict the occurrence of liver
metastases. We found that the primary tumours of patients who
developed liver metastases are characterised not only by sig-
nificantly higher amplifications of chromosome 20q (P¼ 0.003),
but also by significantly lower mutations in the PI(3)K signalling
pathway (P¼ 0.003) and hardly ever CIMP-high (P¼ 0.05). We
revealed a strong inverse association between 20q amplification
and mutations in the PI(3)K pathway.
Chromosome 20q has previously been related to tumour
progression, worse patient survival and observed in liver
metastases (Aust et al, 2004; Bruin et al, 2010). Consequently, a
further understanding of the candidate genes located on chromo-
some 20q amplification may guide us to understand the biological
mechanisms in the development of liver metastases. Several genes
located on 20q, for example, the oncogenes located on 20q13.1,
such as CAS/CSE1L, NABC1, ZNF217, Aurora2 (BTAK, STK15) and
the ubiquitin-conjugating enzyme E2C (UBE2C), have been
described to have an important role in tumour progression and
liver metastases. Interestingly, none of these genes are related to
the PI(3)K signalling pathway and therefore further strengthen the
conclusion that these two phenomena are mutually exclusive (Aust
et al, 2004; Rooney et al, 2004; Takahashi et al, 2006).
Several molecular studies have revealed that KRAS mutation
status influences sensitivity to EGFR-targeted drugs (Normanno
et al, 2009). Based on these findings, the European Medicines
Agency and the US Food and Drug administration have placed
restrictions on the usage of EGFR-targeted drugs and only
approved for CRC metastatic patients with wild-type KRAS
tumours. In patients without KRAS mutation, supplementary
genotyping of BRAF, NRAS and PIK3CA could result in further
improvement of response rates in the treatment with EGFR-
targeted drugs. However, even a combination of all known
Table 3 Co-occurrence in all primary CRC of CIMP, BRAF and MSI
CIMP-low
(n¼ 108)
CIMP-high
(n¼ 23)
Total
(n¼ 131)
P-value
Fisher’s
exact
BRAF
Wild type 98 (91%) 15 (65%) 113 (86%) 0.003
Mutated 5 (5%) 6 (26%) 11 (8%)
Missing 5 (5%) 2 (9%) 7 (5%)
MSI
Stable/low 104 (96%) 17 (74%) 121 (92%) 0.11
High 2 (2%) 2 (9%) 4 (3%)
Missing 2 (2%) 4 (17%) 6 (5%)
Abbreviations: BRAF¼ B-type Raf kinase; CIMP¼CpG-island methylator phenotype;
CRC¼ colorectal cancer; MSI¼microsatellite instability.
Table 4a Co-occurrence in all primary CRC of PI(3)K signalling pathway
mutation and chromosomal amplification of 20q
20q
Low
20q
High Missing All
P-value
Fisher’s exact
No PI(3)K pathway mutation 14 33 15 62 o0.0001
PI(3)K Pathway mutation 31 11 20 62
Missing 1 3 5 9
All 46 47 40 133
Abbreviations: CRC¼ colorectal cancer; PI(3)K¼ phosphoinositide 3-kinase.
Table 4b Co-occurrence in primary CRC of PI(3)K signalling pathway
mutation and chromosomal amplification of 20q for M0+PM vs LM patients
M0+PM LM
20q PI(3)K pathway n % n %
Low Wild type 9 15.8 5 15.6
Mutated 28 49.1 3 9.4
High Wild type 13 22.8 20 62.5
Mutated 7 12.3 4 12.5
Abbreviations: CRC¼ colorectal cancer; LM¼ liver metastasis; PI(3)K¼ phosphoi-
nositide 3-kinase; PM¼ peritoneal metastasis.
Molecular factors associated with colorectal cancer metastases
SC Bruin et al
285
British Journal of Cancer (2011) 105(2), 281 – 287& 2011 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
mutations still leaves more than half of the non-responses
unexplained (De Roock et al, 2010). This together with the results
of our study may suggest that these patients do not depend on the
PI(3)K signalling pathway and therefore might mean that EGFR-
related therapy can be specially appropriate for patients with CRC
liver metastasis.
Patients with LM selected for this study were treated with liver
perfusion. These patients are characterised having multiple and/or
in-operable metastases. This may influence the applicability of our
conclusion for all CRC patients because it is unknown whether the
biology of these patients is different from the overall group of
patients who develop liver metastases. However, we have chosen
this approach because these LM patients were representative for a
group with high specificity for liver metastases development, that
is, multiple metastases confined to the liver.
Despite the fact that patients in this study were selected and may
not represent the general CRC patient population, our findings do
reveal that patients at risk for developing liver metastases could be
identified based on molecular characteristics of the primary
tumour. Such patients should be frequently screened with modern
imaging tools and are most likely to benefit from additional
chemotherapy or targeted drugs. Further research needs to be
carried out to validate these findings in an independent cohort of
patients.
Molecular changes such as the presence of 20q amplification
combined with the absence of mutations in the PI(3)K signalling
pathway and low CIMP in a CRC primary tumour might become a
reason to perform tailored follow-up and eventually targeted
therapy.
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